<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00204620</url>
  </required_header>
  <id_info>
    <org_study_id>jth_002</org_study_id>
    <nct_id>NCT00204620</nct_id>
  </id_info>
  <brief_title>Bendamustin Hydrochloride in Patients With Soft Tissue Sarcoma (STS)</brief_title>
  <official_title>Multicenter Phase II Study With Bendamustin for Patients With Refractory Soft Tissue Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Arbeitsgemeinschaft fur Internistische Onkologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Sarcoma Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <brief_summary>
    <textblock>
      The aims of this trial are to evaluate the efficacy of bendamustin in patients with
      metastatic soft tissue sarcoma who have progressed after or during an anthracycline-baesd
      chemotherapy and to assess the treatment of toxicity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2002</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>28</enrollment>
  <condition>Sarcoma, Soft Tissue</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed metastatic or non-resectable soft tissue sarcoma

          -  Evidence of progression or relapse after an anthracycline-based and/ or
             ifosfamide-based chemotherapy

          -  At least 1 bidimensionally measurable tumor lesion according to RECIST criteria

          -  No previous radiation therapy on the only measurable lesion

          -  Willingness to receive regular follow-up

          -  Life expectancy more than 3 months

          -  ECOG status &gt;= 2

          -  Patients aged 18 years and beyond

          -  leucocytes &gt; 2500/µl, thrombocytes &gt; 75000/µl)

          -  Serum creatine &lt; 1,5 times the upper limit of normal value, GFR &gt; 60/ml

          -  Written patient informed consent

          -  Ability to give informed consent

        Exclusion Criteria:

          -  Previous or concurrent radiation of the index lesion (radiation of single lesion is
             allowed if not the index lesion)

          -  Insufficient liver function (bilirubin &gt; 1.5 the upper limit of normal, prolongation
             of PT and aPTT &gt; 1.5 the upper limit of normal; ASAT and ALAT &gt; 3 the upper limit of
             normal (patients with liver metastases ASAT and ALAT &gt; 5 the upper limit of normal)

          -  Active infection

          -  Prior therapy with Bendamustin hydrochloride

          -  Prior malignancies (other than adequately treated carcinoma in situ (CIS) of the
             cervix, bladder urothelium, basal cell carcinoma or adenoma of the colon including
             pTIS,pTIN), unless treated with curative intent and without evidence of disease &gt; 5
             years

          -  Symptomatic cardio- and/or cerebrovascular disease (NYHA-Scale III°)

          -  Interval since last chemotherapy &lt; 4 weeks

          -  Evidence of CNS-metastases

          -  Evidence of pregnancy or lactation

          -  Woman of child-bearing potential without reliable methods of birth control
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joerg T Hartmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>South West German Cancer Center, Medical Center II, University of Tuebingen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical center II, University of Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>April 19, 2007</last_update_submitted>
  <last_update_submitted_qc>April 19, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

